After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However, the biologic ...

Argatroban could revive the practice of acute anticoagulation for reducing disability after stroke, based on the EASE trial from China. In patients with acute ischemic stroke and early neurological ...

(San Diego, Calif., December 7, 2003) – The use of ximelagatran in patients with acute venous thromboembolism is as safe and effective as the current standard treatment of enoxaparin, according to a ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Potent new anticoagulants have been discovered in the genetic code responsible for the saliva of blood-sucking ticks. Anticoagulants, also known as blood thinners, help prevent unwanted blood clotting ...

Direct thrombin inhibitors prevent the conversion of fibrinogen into fibrin during the coagulation cascade and ultimately prevent the development of a thrombus. 11 Dabigatran etexilate was the first ...

Coadministration of dabigatran etexilate with the antiplatelet drug clopidogrel had no effect on dabigratran's anticoagulant activity as measured by ECT, activated partial thromboplastin time (aPTT), ...

Thrombosis, the clogging of blood vessels, is a major cause of heart attacks and embolism. Scientists have now engineered the first inhibitors of thrombin, a protease promoting thrombosis, that is ...

Among patients with atrial fibrillation (AF), use of factor Xa inhibitors for stroke prevention is associated with a greater risk of interstitial lung disease (ILD) than use of warfarin, although the ...